TY - JOUR
T1 - Evaluation of the Antioxidant Activity of Levetiracetam in a Temporal Lobe Epilepsy Model
AU - Ignacio-Mejía, Iván
AU - Contreras-García, Itzel Jatziri
AU - Mendoza-Torreblanca, Julieta Griselda
AU - Medina-Campos, Omar Noel
AU - Pedraza-Chaverri, José
AU - García-Cruz, Mercedes Edna
AU - Romo-Mancillas, Antonio
AU - Gómez-Manzo, Saúl
AU - Bandala, Cindy
AU - Sánchez-Mendoza, María Elena
AU - Pichardo-Macías, Luz Adriana
AU - Cárdenas-Rodríguez, Noemí
N1 - Publisher Copyright:
© 2023 by the authors.
PY - 2023/3
Y1 - 2023/3
N2 - Epilepsy is a neurological disorder in which it has been shown that the presence of oxidative stress (OS) is implicated in epileptogenesis. The literature has shown that some antiseizure drugs (ASD) have neuroprotective properties. Levetiracetam (LEV) is a drug commonly used as an ASD, and in some studies, it has been found to possess antioxidant properties. Because the antioxidant effects of LEV have not been demonstrated in the chronic phase of epilepsy, the objective of this study was to evaluate, for the first time, the effects of LEV on the oxidant–antioxidant status in the hippocampus of rats with temporal lobe epilepsy (TLE). The in vitro scavenging capacity of LEV was evaluated. LEV administration in rats with TLE significantly increased superoxide dismutase (SOD) activity, increased catalase (CAT) activity, but did not change glutathione peroxidase (GPx) activity, and significantly decreased glutathione reductase (GR) activity in comparison with epileptic rats. LEV administration in rats with TLE significantly reduced hydrogen peroxide (H2O2) levels but did not change lipoperoxidation and carbonylated protein levels in comparison with epileptic rats. In addition, LEV showed in vitro scavenging activity against hydroxyl radical (HO•). LEV showed significant antioxidant effects in relation to restoring the redox balance in the hippocampus of rats with TLE. In vitro, LEV demonstrated direct antioxidant activity against HO•.
AB - Epilepsy is a neurological disorder in which it has been shown that the presence of oxidative stress (OS) is implicated in epileptogenesis. The literature has shown that some antiseizure drugs (ASD) have neuroprotective properties. Levetiracetam (LEV) is a drug commonly used as an ASD, and in some studies, it has been found to possess antioxidant properties. Because the antioxidant effects of LEV have not been demonstrated in the chronic phase of epilepsy, the objective of this study was to evaluate, for the first time, the effects of LEV on the oxidant–antioxidant status in the hippocampus of rats with temporal lobe epilepsy (TLE). The in vitro scavenging capacity of LEV was evaluated. LEV administration in rats with TLE significantly increased superoxide dismutase (SOD) activity, increased catalase (CAT) activity, but did not change glutathione peroxidase (GPx) activity, and significantly decreased glutathione reductase (GR) activity in comparison with epileptic rats. LEV administration in rats with TLE significantly reduced hydrogen peroxide (H2O2) levels but did not change lipoperoxidation and carbonylated protein levels in comparison with epileptic rats. In addition, LEV showed in vitro scavenging activity against hydroxyl radical (HO•). LEV showed significant antioxidant effects in relation to restoring the redox balance in the hippocampus of rats with TLE. In vitro, LEV demonstrated direct antioxidant activity against HO•.
KW - antioxidant
KW - levetiracetam
KW - neuroprotection
KW - temporal lobe epilepsy
UR - http://www.scopus.com/inward/record.url?scp=85152006345&partnerID=8YFLogxK
U2 - 10.3390/biomedicines11030848
DO - 10.3390/biomedicines11030848
M3 - Artículo
C2 - 36979827
AN - SCOPUS:85152006345
SN - 2227-9059
VL - 11
JO - Biomedicines
JF - Biomedicines
IS - 3
M1 - 848
ER -